Press releases

Financial overview

Second quarter, Q2 2022, Group (formed on 1 March 2022)

• Net sales amounted to 0.
• Other operating income amounted to TSEK 2,311.
• The result after tax amounted to TSEK -7,054.
• Basic and diluted earnings per share amounted to: SEK -0.03.
• Cash flow from operating activities was TSEK -10,210.
• Cash and cash equivalents amounted to TSEK 75,530 as of 30 June 2022.

Second quarter, Q2 2022, Parent Company 

• Net sales amounted to 0 (0).
• Other operating income amounted to TSEK 56 (48).
• The result after tax amounted to TSEK -4,679 (-2,132).
• Basic and diluted earnings per share amounted to: SEK -0.02 (-0.01).
• Cash flow from operating activities was TSEK -6,560 (-1,631).
• Cash and cash equivalents amounted to TSEK 73,124 (48,224) as of 30 June 2022.

Prolight Diagnostics is pleased to announce successful recruitments to four key positions in its fully owned UK subsidiary Psyros Diagnostics. As previously announced, the company was acquired in the beginning of the year and the work on the continuous development of Psyros' unique digital immunoassay platform is progressing according to plan. Three of the new recruits are already in full employment: Senior Scientist Marc Swayne, Systems Engineer Sam Fincham and Mechanical Engineer Daniel Hollands.

Prolight Diagnostics AB has today signed an agreement to acquire UK-based Psyros Diagnostics Ltd for 65 MSEK (ca. £5.25M). Psyros Diagnostics has developed a ground-breaking single-molecule counting Point-of-Care (POC) technology. This patent-pending and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations (femtomolar 10^-15) in approximately 10 minutes or less.

Financial overview